Maze Therapeutics (NASDAQ:MAZE) Stock Jumps 5.5% – Still a Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price shot up 5.5% during trading on Monday. The company traded as high as $28.49 and last traded at $29.0450. 122,329 shares were traded during trading, a decline of 82% from the average daily volume of 670,087 shares. The stock had previously closed at $27.53.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of recent research reports. Canaccord Genuity Group initiated coverage on shares of Maze Therapeutics in a report on Monday. They issued a “buy” rating and a $75.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. HC Wainwright reiterated a “buy” rating and issued a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 24th. Finally, Wedbush reissued an “outperform” rating and set a $48.00 price target on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $64.45.

Maze Therapeutics Stock Up 5.6%

The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The firm has a 50-day simple moving average of $26.76 and a 200 day simple moving average of $27.01. The stock has a market capitalization of $1.61 billion, a P/E ratio of -11.59 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). On average, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.70 EPS for the current year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the transaction, the insider directly owned 26,250 shares in the company, valued at approximately $723,975. This represents a 22.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the transaction, the chief executive officer owned 18,151 shares in the company, valued at $477,189.79. The trade was a 65.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 192,991 shares of company stock valued at $5,152,084 over the last quarter. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. increased its stake in Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares in the last quarter. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics during the second quarter worth approximately $133,502,907. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics during the second quarter worth approximately $122,983,582. BlackRock Inc. bought a new position in shares of Maze Therapeutics in the 2nd quarter worth $104,525,000. Finally, Jupiter Topco LLC acquired a new stake in Maze Therapeutics in the 2nd quarter valued at $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.